Metastatic hormone-naïve prostate cancer: a distinct biological entity.
Trends Cancer
; 2024 Jul 23.
Article
in En
| MEDLINE
| ID: mdl-39048488
ABSTRACT
Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response to therapy. A more precise treatment of mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, the limited number of representative laboratory models of mHNPC hampers the translation of basic research into clinical applications. We provide a comprehensive overview of the clinical and biological features that characterize mHNPC, highlight molecular data that could explain the unique prognostic characteristics of mHNPC, and identify key open questions.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Trends Cancer
Year:
2024
Document type:
Article
Affiliation country:
España